Bicycle Therapeutics is a biotechnology company developing a platform technology that enables the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals to create highly specific and highly stable drugs.
Applying phage selection techniques to repertoires of chemically constrained cyclic peptides allows the identification and optimisation of molecules with high target specificity and binding affinity that are also stable to unfolding and to the action of proteases. These peptides could be regarded as a mini-antibodies with covalent organic cores, and as such should overcome the weaknesses of previous generations of peptide based therapeutics.
Bicycle Therapeutics is a spin-out from the Medical Research Council Laboratory of Molecular Biology, Cambridge, based on the pioneering work of the founding scientists Sir Gregory Winter and Dr.Christian Heinis. Bicycle Therapeutics is managed by Dr. Rolf Günther (Chief Executive Officer) and is based in Cambridge.